Ipsen: Neoplasms trials

The registry lists 11 Neoplasms studies with Ipsen as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 8Phase 2 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsCompletedNCT04537715Phase 1Results posted
• Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid TumoursTerminatedNCT03894540Phase 1Results posted
• Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgCompletedNCT02651987Phase 2Results posted
• A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaCompletedNCT02601950Phase 2Results posted
• EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaCompletedNCT02601937Phase 1Results posted
• A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
• Tazemetostat Expanded Access Program for Adults With Epithelioid SarcomaNo longer availableNCT04225429
• A Phase 1b/2a Study Evaluating AMG 232 in Metastatic MelanomaCompletedNCT02110355Phase 1
• A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaCompletedNCT02016729Phase 1
• A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaCompletedNCT01723020Phase 1
• BN80927 in Patients With Advanced Malignant Solid TumorsCompletedNCT01435096Phase 1